Cancer Network | Bladder Cancer Patient on Everolimus Has Complete Response Cancer Network In a phase I trial, a bladder cancer patient has had a 14-month complete response with the combination of the mTOR inhibitor everolimus and pazopanib, a selective multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis, including ... Patient with advanced bladder cancer shows complete response to everolimus ... Exceptional Responder Provides Treatment Clues in Bladder Cancer Genomic testing links 'exceptional' drug response to rare mutations in bladder ... |
